Vanguard Global Advisers’s Quince Therapeutics QNCX Stock Holding History

Vanguard Global Advisers’s Portfolio QNCX Stock Details QNCX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-98	Closed	-$1.97K	–	3715
2026 Q1	$1.97K	Buy	+98	New	+$19.7K	﹤0.01%	3616

Other funds holding QNCX

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Vanguard Global Advisers's QNCX Position: Q2 2026 in Review

Vanguard Global Advisers sold out of Quince Therapeutics (QNCX) in Q2 2026, closing a stake of 98 shares — an estimated $1.97K sold.

Vanguard Global Advisers first reported a position in QNCX in Q1 2026 and held it in 1 quarter. The position peaked at $1.97K in Q1 2026. 25 funds tracked by Wall St. Rank hold QNCX as of Q2 2026.

Vanguard Global Advisers reported no remaining Quince Therapeutics position as of Q2 2026 after selling out during the quarter.
Vanguard Global Advisers sold 98 Quince Therapeutics shares in Q2 2026, an estimated $1.97K.
Vanguard Global Advisers first reported a position in Quince Therapeutics in Q1 2026 and held it in 1 quarter.
Vanguard Global Advisers's Quince Therapeutics position peaked at $1.97K in Q1 2026.
25 funds tracked by Wall St. Rank held Quince Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.